摘要
目的探讨沙美特罗替卡松(舒利迭)联合孟鲁斯特钠(顺尔宁)对慢性阻塞性肺疾病(COPD)患者肺功能的影响。方法40例患者随机分为舒利迭组(对照组)和舒利迭加顺尔宁组(试验组)各20例。两组入院期间均给于常规抗感染、吸氧、化痰和平喘对症治疗。对照组加用舒利迭,试验组加用舒利迭和顺尔宁,两组平喘治疗包括普通氨茶碱,按需使用喘康速气雾剂(特布他林)。出院后对照组继续使用舒利迭,试验组继续使用舒利迭和顺尔宁,共随访观察12周。两组均于治疗前查肺功能,治疗症状好转出院,12周后再次测定上述指标。结果两组治疗前肺功能无明显差异;治疗后两组肺功能较治疗前均有显著改善。试验组较对照组第一秒用力呼气容积(FEV1)、用力肺活量(FVC)、第一秒用力呼气容积/用力肺活量(FEV1/FVC)和第一秒用力呼气容积占预计值百分比(FEV1%Pred)等明显改善,差异有显著性;试验组较对照组每天按需使用特布他林次数减少,差异有显著性。结论舒利迭和顺尔宁共同作用对COPD患者肺功能更有显著的改善作用。
Objective To explore the effects of combining salmeterel/flnticasone propionate （seretide） and montelukast sodium （singulair） on patients with COPD by analyzing lung function. Methods 40 patients with COPD were randomly divided into two groups ： experimental group （20 cases） and control group （20 cases）. The basic treatments for the two groups were antibiotics, oxygens inhalation, dissipate phlegm and antiasthma etc. The control group was given seretide; the experimental group was given seretide and singulair. Antiasthma treatments included aminophylline and bricasol （terbutaline） pro re nata. After leaving hospital, the control group continued using seretide; the experimental group continued using seretide and singulair for 12 weeks. All patients checked lung function before the treatment ; Lung function was checked after 12 weeks. Results Before the treatment, lung function in the both groups were not statistically different （ P 〉 0. 05 ）. After the treatment, there was improvement of lung function than before the treatment （ P 〈 0. 05 ）. FEV1 , FVC, FEV1/FVC and FEV1% Pred were superior in the experimental group to the control group. The experimental group used bricasol （terbutaline） less than the control group. Conclusion Combining seretide and singulair can improve lung fuction significantly.
出处
《临床肺科杂志》
2009年第8期1032-1034,共3页
Journal of Clinical Pulmonary Medicine
关键词
COPD
沙美特罗替卡松(舒利迭)
孟鲁斯特钠(顺尔宁)
肺功能
chronic obstructive pulmonary disease （COPD）
salmeterol/fluticasone propionate （seretide）
montelukast sodium （singulair）
lung function
